|
Video: What is a Stock Split?
|
|
Omeros is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing small-molecule and protein therapeutics targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The primary drug candidate in its pipeline of complement-targeted therapeutics is narsoplimab, a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy. According to our OMER split history records, Omeros has had 0 splits. | |
|
Omeros (OMER) has 0 splits in our OMER split history database.
Looking at the OMER split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Omeros shares, starting with a $10,000 purchase of OMER, presented on a split-history-adjusted basis factoring in the complete OMER split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$12.48 |
|
End price/share: |
$3.45 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-72.36% |
|
Average Annual Total Return: |
-12.07% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$2,763.91 |
|
Years: |
10.00 |
|
|
|
|
|